Results 191 to 200 of about 22,527 (249)

A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease [PDF]

, 2003
Nina Vasavada, Chandan Saha, Rajiv Agarwal   +2 more
openalex   +1 more source

Blood Pressure Effects and Risk of Hypotension due to Intravenous Furosemide in Acute Decompensated Heart Failure

Academic Emergency Medicine, EarlyView.
ABSTRACT Objective We quantified the magnitude of systolic blood pressure (SBP) adverse effects associated with intravenous furosemide (IVFu), compared to other factors, during treatment for acute decompensated heart failure (ADHF). Methods Continuous BP monitoring (598.2 person‐hours, 91,210 observations) before and after IVFu was performed in a ...
Nicholas E. Harrison, Meghana Bhaskara, Kyle Wilson, Ankit A. Desai, Nicholas Montelauro, Phillip Levy, Peter Pang, Robert R. Ehrman   +7 more
wiley   +1 more source

Severe Hyponatremia in the Emergency Department Incidence of Cerebral Edema and Risk of Osmotic Demyelination Syndrome

Academic Emergency Medicine, EarlyView.
ABSTRACT Study Objective Treatment strategies in severe hyponatremia aim at rapid sodium correction to prevent or treat cerebral edema but limit sodium rise to prevent osmotic demyelination syndrome (ODS). The true risk of edema or ODS in ED patients is unknown.
Volker Burst, Ramon Rabii, Julian Peto‐Madew, Thorsten Persigehl, Stefan Haneder, Matthias Johannes Hackl, Christoph Hüser, Moritz Trappe, Sadrija Cukoski, Kathrin Möllenhoff, Victor Suárez   +10 more
wiley   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure: Priming the Natriuretic and Metabolic Reserve of the Kidney. [PDF]

Circulation, 2020
Grodin JL, Tang WHW.
europepmc   +1 more source

Urinary Calcium and Phosphorus Excretion in Vitamin D‐Sufficient Preterm Infants: Establishing Age‐Specific Normative Data

Acta Paediatrica, EarlyView.
ABSTRACT Aim This study evaluated urinary calcium (Ca) and phosphorus (P) excretion in very low birth weight infants ( < 1500 g, VLBW) without severe morbidity, treated with methylxanthines. Methods Eighty‐one VLBW infants were analysed. Urinary Ca and P and their creatinine ratios were measured biweekly until day 56.
Tomas Matejek, Veronika Pokorna, Vojtech Drahy, Lenka Zaloudkova, Vladimir Palicka, Sylva Skalova   +5 more
wiley   +1 more source

Co-Administration of Drugs and Parenteral Nutrition: In Vitro Compatibility Studies of Loop Diuretics for Safer Clinical Practice. [PDF]

Pharmaceutics, 2020
Tomczak S, Stawny M, Jelińska A.
europepmc   +1 more source

Mass Spectrometric Measurements of 11‐Deoxycortisol, Androstenedione and Dehydroepiandrosterone Are Superior to Cortisol to Assess Selectivity of Non‐Stimulated Adrenal Vein Sampling

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Successful adrenal venous sampling (AVS) is traditionally assessed using the ratio of cortisol in adrenal to peripheral venous plasma to calculate the selectivity index. With mass spectrometry other steroids can be simultaneously measured that may improve numbers of apparent successful sampling procedures.
Francesco Alessi, Christina Pamporaki, Mirko Peitzsch, Georgiana Constantinescu, Hanna Remde, Lydia Kürzinger, Carmina T. Fuss, Manuel Schulze, Sybille Fuld, Sradha Kotwal, Jun Yang, Martin Reincke, Felix Beuschlein, Jacques W. M. Lenders, Graeme Eisenhofer   +14 more
wiley   +1 more source

The independent association between altered renal arterial resistance and loop diuretic dose in chronic heart failure outpatients

, 2015
Massimo Iacoviello, Annalisa Doronzo, Valeria Paradies, Valeria Antoncecchi, Francesco Monitillo, Gaetano Citarelli, Marta Leone, Agata Puzzovivo, Loreto Gesualdo, Marco Matteo Ciccone   +9 more
openalex   +1 more source

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source